新型序贯无创纤维化检测组合可准确诊断NAFLD进展期纤维化
在938例经活检证实的非酒精性脂肪性肝病(NAFLD)患者中,按2:1随机分为推导集和验证集,评估振动控制瞬时弹性成像(VCTE)与血液纤维化检测组合诊断进展期纤维化的准确性。FibroMeterVCTE优于VCTE和血液检测,FIB4-FMVCTE和VCTE-FMVCTE序贯算法诊断准确率达90%,仅20%病例需肝活检确认。
要点
- VCTE诊断进展期纤维化准确性显著优于血液检测(AUROC 0.840±0.013,p≤0.005)。
- FibroMeterVCTE联合检测优于VCTE和血液检测(AUROC 0.866±0.012,p≤0.005)。
- FIB4-FMVCTE和VCTE-FMVCTE序贯算法诊断准确率90%,仅20%病例需肝活检确认。
核心结论
- FIB4-FMVCTE和VCTE-FMVCTE序贯组合算法为NAFLD进展期纤维化诊断提供了高准确度方案。
- 这些算法尚需在糖尿病科或初级保健环境中验证其诊断进展期肝纤维化的效能。
研究设计与样本
- 共纳入938例经活检证实的NAFLD患者,按2:1随机分为推导集和验证集。
- 所有患者均接受VCTE肝硬度检测及血液纤维化检测(NAFLD纤维化评分、FIB4、Fibrotest、Hepascore、FibroMeter),并计算FibroMeterVCTE。
主要发现
- 诊断进展期纤维化,VCTE准确性显著优于血液检测(AUROC 0.840±0.013,p≤0.005)。
- FibroMeter为最准确的血液检测(AUROC 0.793±0.015,p≤0.017)。
- FibroMeterVCTE联合检测优于VCTE和血液检测(AUROC 0.866±0.012,p≤0.005)。
- FIB4-FMVCTE或VCTE-FMVCTE序贯组合诊断进展期纤维化准确率达90%,仅20%病例需肝活检确认。
- FIB4-FMVCTE和VCTE-FMVCTE算法准确性显著优于目前提出的实用性算法。
临床怎么用
- 作者认为FIB4-FMVCTE和VCTE-FMVCTE序贯算法为NAFLD进展期纤维化诊断提供了高准确度方案。
- 作者建议这些算法应在糖尿病科或初级保健环境中验证其诊断进展期肝纤维化的效能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Advanced liver fibrosis is an important diagnostic target in non-alcoholic fatty liver disease (NAFLD) as it defines the subgroup of patients with impaired prognosis. The non-invasive diagnosis of advanced fibrosis is currently limited by the suboptimal positive predictive value and the grey zone (representing indeterminate diagnosis) of fibrosis tests. Here, we aimed to determine the best combination of non-invasive tests for the diagnosis of advanced fibrosis in NAFLD. METHODS: A total of 938 patients with biopsy-proven NAFLD were randomized 2:1 into derivation and validation sets. All patients underwent liver stiffness measurement with vibration controlled transient elastography (VCTE) and blood fibrosis tests (NAFLD fibrosis score, Fibrosis-4 [FIB4], Fibrotest, Hepascore, FibroMeter). FibroMeterVCTE, which combines VCTE results and FibroMeter markers in a single test, was also calculated in all patients. RESULTS: For the diagnosis of advanced fibrosis, VCTE was significantly more accurate than the blood tests (area under the receiver operating characteristic curve [AUROC]: 0.840 ± 0.013, p ≤0.005). FibroMeter was the most accurate blood test (AUROC: 0.793 ± 0.015, p ≤0.017). The combinatory test FibroMeterVCTE outperformed VCTE and blood tests (AUROC: 0.866 ± 0.012, p ≤0.005). The sequential combination of FIB4 then FibroMeterVCTE (FIB4-FMVCTE algorithm) or VCTE then FibroMeterVCTE (VCTE-FMVCTE algorithm) provided an excellent diagnostic accuracy of 90% for advanced fibrosis, with liver biopsy only required to confirm the diagnosis in 20% of cases. The FIB4-FMVCTE and VCTE-FMVCTE algorithms were significantly more accurate than the pragmatic algorithms currently proposed. CONCLUSION: The sequential combination of fibrosis tests in the FIB4-FMVCTE and VCTE-FMVCTE algorithms provides a highly accurate solution for the diagnosis of advanced fibrosis in NAFLD. These algorithms should now be validated for the diagnosis of advanced liver fibrosis in diabetology or primary care settings. LAY SUMMARY: The evaluation of liver fibrosis is mandatory in non-alcoholic fatty liver disease (NAFLD), as advanced fibrosis identifies the subgroup of patients with impaired prognosis. FibroMeterVCTE is a new fibrosis test combining blood markers and the result of vibration controlled transient elastography (VCTE) into a single diagnostic test. Our results show that FibroMeterVCTE outperforms other blood fibrosis tests and VCTE alone for the diagnosis of advanced fibrosis in a large multi-centric cohort of 938 patients with biopsy-proven NAFLD. Sequential algorithms using a simple blood test or VCTE as a first-line procedure, then FibroMeterVCTE as a second-line test accurately classified 90% of patients.
引用
- Boursier J, Guillaume M, Leroy V, et al. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. J Hepatol. 2019. PMID: 31102719. doi:10.1016/j.jhep.2019.04.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。